Calamos Advisors
AVDL

Calamos Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Calamos Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-106,776
Closed -$862K – 707
2020
Q2 		$862K Buy
+106,776
New +$941K 0.01% 646

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Calamos Advisors's AVDL Position: Q3 2020 in Review

Calamos Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q3 2020, closing a stake of 106,776 shares — an estimated $862K sold.

Calamos Advisors first reported a position in AVDL in Q2 2020 and held it in 1 quarter. The position peaked at $862K in Q2 2020. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.

  • Calamos Advisors reported no remaining Avadel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Calamos Advisors sold 106,776 Avadel Pharmaceuticals shares in Q3 2020, an estimated $862K.
  • Calamos Advisors first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Calamos Advisors's Avadel Pharmaceuticals position peaked at $862K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.

Based on Calamos Advisors's 13F filing for Q3 2020, filed 26 Oct 2020.